A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Stephanie I KimAndy H SzetoKatherine P MorganBlaine BrowerMary W DunnAmir H KhandaniPaul A GodleyTracy L RoseEthan M BaschMatthew I MilowskyYoung E WhangDaniel J CronaPublished in: PloS one (2021)
Combination radium-223 plus abiraterone or enzalutamide did not improve overall survival, but prolonged progression-free survival without increasing the incidence of serious adverse events in metastatic castration-resistant prostate cancer patients with bone metastases. However, these results are limited by small numbers and patient selection inherent in retrospective analysis.